Wuhan HITECK biopharmaceutical Co., Ltd.

Wuhan HITECK biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise with the goal of building an excellent innovative biopharmaceutical enterprise in China. It was listed on the main board of Shenzhen Stock Exchange on August 8, 2017 (stock abbreviation: HITECK biopharmaceutical, stock code: 300683). The main business is the production and sales of bioengineering products and freeze-dried powder injection; The company's products and technology import and export business. At present, the company has 25 production numbers of biological products and chemicals.

The company Park covers an area of 138000 square meters, with an existing construction area of more than 61000 square meters. It has a production plant of more than 14800 square meters in line with the national GMP standards, with complete facilities and first-class equipment. In order to realize the company's quality policy and optimize product quality, the company has established a quality management department with sound functions to carry out drug production and total quality management in strict accordance with GMP requirements. At present, the group has more than 1000 employees, 76% of whom have college degree or above. Some university professors work in enterprises and have established project cooperation relations with many famous academicians. The company has established a core cultural system, and works together with its employees to cultivate high-quality management personnel and engineering technicians with "integrity, gratitude, professionalism and enterprising".

The company is a high-tech enterprise in Hubei Province. There are post doctoral mobile workstations approved by the Ministry of human resources and social security of the people's Republic of China, and "Hubei rare disease drug engineering technology research center" and "Hubei high tech innovative enterprise" approved by the provincial science and technology department. Five basic technology platforms have been established, and pilot bases have been established to promote the industrialization of relevant achievements and efficient transformation to the market.

The company is based on the R & D and production of drugs in the fields of nervous system and oncology. At present, a national class I biological new drug, mouse nerve growth factor for injection (Jinlujie), and a class I genetic engineering biological new drug, recombinant mutant human tumor necrosis factor related apoptosis inducing ligand (CPT), have been put on the market for sale. Phase III clinical blinding work has been completed and the application for production approval is in the preparation stage.

The company adheres to the enterprise tenet of "fearing life and innovation", practices the enterprise values of "integrity, gratitude, professionalism and enterprising", and strives to build HITECK bio into the best innovative drug enterprise in China. The company will expand in the fields of macromolecular drugs, small molecule drugs, in vitro diagnosis, etc., take serving patients as its own responsibility, take continuous innovation as the guide, and build HITECK bio into a first-class pharmaceutical enterprise group!